News | July 12, 2025
Briefs: Emcure Pharmaceuticals and Gland Pharma
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
It is intended for contrast enhancement in MRI scans
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
These medicines are essential in preventing RhD immunisation during pregnancy
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated
